OSI DPP-IV Inhibitor Is A “Sensible Approach” To Diabetes Dosing, Firm Says
The meal-related dosing schedule of OSI Pharmaceuticals' type 2 diabetes candidate PSN9301 could lead to better patient compliance, the company said
The meal-related dosing schedule of OSI Pharmaceuticals' type 2 diabetes candidate PSN9301 could lead to better patient compliance, the company said